Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 B. pertussis human challenge study

Next Previous
Trial Profile

A Phase 3 B. pertussis human challenge study

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 30 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BPZE 1 (Primary)
  • Indications Pertussis
  • Focus Therapeutic Use

Most Recent Events

  • 27 Jan 2025 According to an ILiAD Biotechnologies media release, company announced that following a December 2024 Type C meeting with the United States Food and Drug Administration (FDA), ILiAD and hVIVO plc (hVIVO) have signed a Letter of Intent (LOI) to conduct a pivotal Phase 3 BPZE1 human challenge trial.
  • 04 Dec 2024 According to an ILiAD Biotechnologies media release, the company is currently working with global regulators to finalize Phase 3 BPZE1 clinical trial protocols to support licensure, with a goal of initiating a pivotal study in 2025.
  • 24 Jun 2024 According to an ILiAD Biotechnologies media release, company announced the selection of Emmes Group, a global contract research and technology organization, to conduct upcoming Phase III studies of its lead pertussis vaccine candidate, BPZE1. ILiAD and Emmes Group are currently working to finalize the definitive agreement.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top